Literature DB >> 3838675

Variability of caffeine metabolism in humans.

W Kalow.   

Abstract

The metabolic disappearance of caffeine from blood is subject to substantial inter- and intra-individual variation. Smoking of cigarettes and other inducers of aryl hydrocarbon hydroxylase tend to enhance the caffeine metabolism; pregnancy, the use of oral contraceptives, and various kinds of liver disease prolong the caffeine half-life. A genetic component affecting caffeine half-life has not yet been systematically searched for, but might be expected to affect the response to cigarette smoke and similar inducing agents, rather than to provide direct control of caffeine metabolism. The secondary metabolisms of the primary caffeine metabolites are strongly affected by the well-known genetic polymorphism of the N-acetyltransferase of human liver (a polymorphism originally discovered by studies of isoniazid metabolism). Since the proportion of slow acetylators differs in different ethnic populations, many ethnic differences in the ultimate fate of caffeine are to be expected. An observed difference of paraxanthine excretion between Caucasian and Oriental subjects might reflect a difference in the capacity for renal tubular reabsorption of that substance, but further metabolic differences cannot be excluded. The renal elimination of the dimethylxanthines is urinary flow dependent while that of the water soluble metabolites 1-methylxanthine and AFMU (5-acetylamino-6-formylamino-3-methyluracil) is not. Thus, the urinary metabolite pattern can be expected to vary from time to time. However, habitual coffee intake does not affect the metabolite pattern of caffeine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838675

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

Review 1.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

2.  Analgesic effects of propyphenazone in comparison to its combination with caffeine.

Authors:  H G Kraetsch; T Hummel; J Lötsch; R Kussat; G Kobal
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects.

Authors:  M Bruce; N Scott; M Lader; V Marks
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

4.  The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers.

Authors:  G H Kamimori; S M Somani; R G Knowlton; R M Perkins
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Caffeine physical dependence: a review of human and laboratory animal studies.

Authors:  R R Griffiths; P P Woodson
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.

Authors:  C Cazeneuve; G Pons; E Rey; J M Treluyer; T Cresteil; G Thiroux; P D'Athis; G Olive
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

7.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

8.  Incidence of bladder cancer in a cohort of workers exposed to 4-chloro-o-toluidine while synthesising chlordimeform.

Authors:  W Popp; W Schmieding; M Speck; C Vahrenholz; K Norpoth
Journal:  Br J Ind Med       Date:  1992-08

Review 9.  Validation of biomarkers of food intake-critical assessment of candidate biomarkers.

Authors:  L O Dragsted; Q Gao; A Scalbert; G Vergères; M Kolehmainen; C Manach; L Brennan; L A Afman; D S Wishart; C Andres Lacueva; M Garcia-Aloy; H Verhagen; E J M Feskens; G Praticò
Journal:  Genes Nutr       Date:  2018-05-30       Impact factor: 5.523

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.